Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Inclusion Criteria

• Inclusion Criteria: For subjects with LBCL: - Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017 - At least 1 measurable lesion at time of enrollment - Relapsed or refractory disease after at least 2 lines of chemotherapy - Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening (Note: Only applicable for Phase 2) For subjects with CLL/SLL: - Diagnosis of CLL/SLL - Relapsed/refractory disease - Subjects relapsed/refractory to BTKi therapy and high-risk disease - Subjects relapsed/refractory with 2 or more lines of therapy including BTKi and BCL-2 inhibitor (venetoclax) - At least 1 measurable lesion at time of enrollment For all subjects: - Male or female subjects ≥18 years of age - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 - Adequate hematological, renal, and liver function Exclusion Criteria: - Active central nervous system (CNS) involvement by malignancy - Current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy - Any other active malignancies that required systemic treatment within 3 years prior to enrollment - Radiation therapy within 2 weeks prior to ALLO-647 - Prior irradiation to >25% of the bone marrow - Hypocellular bone marrow for age by institutional standard as determined from a bone marrow biopsy performed at time of screening (Note: Only applicable for Phase 2). - Autologous hematopoietic stem cell transplant (HSCT) within last 6 months (24 weeks) - Systemic anti-cancer therapy within 2 weeks prior to receiving ALLO-647